Abstract Mutations in any of the five genes KCNQ1, KCNH2, KCNE1, KCNE2, and SCN5A can be responsible for familial long QT syndrome (LQTS), an arrhythmogenic disorder that entails a high risk of sudden death. -Adrenergic blocking agents are the first therapeutic choice, and 80% of patients treated with these agents show symptomatic relief; however the remaining 20% do not respond well. We previously performed a nationwide analysis of familial long QT syndrome (LQTS) in Japan and identified 32 mutations in the KCNQ1 and KCNH2 genes. In the present retrospective study, we found that patients carrying mutations in the KCNQ1 gene responded better to -adrenergic blocking agents than those with KCNH2 mutations (12 of 13 vs 1 of 5; P ϭ 0.0077, Fisher's exact test). This is a good example of the power of genetic diagnosis to direct the selection of appropriate therapy for patients with diseases of heterogeneous genetic etiology.
Introduction
Familial long QT syndrome (LQTS) is an autosomal dominant arrhythmogenic disorder carrying a high risk of syncope and sudden death. In recent years, five responsible genes (KCNQ1, KCNH2, KCNE1, KCNE2, and SCN5A; Wang et al. 1996; Curran et al. 1995; Splawski et al. 1997; Schulze-Bahr et al. 1997; Abbott et al. 1999; Wang et al. 1995) have been identified; four of them encode cardiac potassium channels, and the fifth (SCN5A) encodes sodium channels. Although another genetic locus has also been identified on chromosome 4 (Schott et al. 1995) , the gene responsible has not yet been found. According to previous reports, including ours (for review, see "The long QT syndrome database" home page, under approval of Human Genome Organisation (HUGO); http://www.ssi.dk/ en/forskning/lqtsdb/lqtsdb.htm), KCNQ1 and KCNH2 represent about half and about 40%, respectively, of the total mutations found in LQTS. The three other genes seem to play a relatively less important role in the pathogenesis of LQTS. In a previous nation-wide analysis of familial LQTS, we ascertained 114 LQTS families throughout Japan, obtaining their informed consent for genetic analysis. In the process of mutational analyses for the five genes noted above, we identified 32 different mutations, 16 in the KCNQ1 gene and 16 in KCNH2 (Tanaka et al. 1997; Itoh et al. 1998a; Itoh et al. 1998b ; our unpublished data) in our population sample; we found no mutations in any other of the genes associated with LQTS.
As a preventive measure, -adrenergic blockade is generally the first therapeutic choice; about 80% of LQTS patients show symptomatic relief with drug treatment (Locati and Schwartz 1992) . However, the remaining 20% show poor response to -blockers and require more intensive therapy, such as the implantation of an automatic internal cardioverter-defibrillator (AICD). The variability of QT intervals and clinical signs among carriers of the genes responsible for LQTS makes accurate diagnosis difficult (Vincent et al. 1992 ), but early diagnosis and preventive therapy is crucial for protecting these patients from sudden cardiac death. Hence, if the different responses toblockers reflect mutations at different sites within a given gene, or mutations in different genes, genetic diagnosis might provide information to govern the choice of an appropriate therapeutic approach.
In an effort to clarify a possible genotype/phenotype relationship, we retrospectively looked for a correlation between genetic etiology and response to drug treatment. Here we describe the one which should be of use in the choice of therapy.
Patients and methods

Selection of patients
To search for a genotype/phenotype relationship, we first selected LQTS patients who had been identified in our previous studies and in our unpublished data as carriers of mutations in the genes responsible (Tanaka et al. 1997; Itoh et al. 1998a; Itoh et al. 1998b ). Then, we chose patients with histories of syncope who had received simple -adrenergic blockade therapy, to investigate the effectiveness of this therapy. Those patients who showed no episodes of syncope throughout the follow-up period, after taking a -blocker were considered responders. As described in our previous reports, all patients gave their informed consent before they were enrolled in this study.
Statistical analysis
Statistical analysis was performed using Fisher's exact test. P values under 0.05 were considered significant. Tanaka et al. (1997) , Itoh et al. (1998a) , and Itoh et al. (1998b) Results and discussion The results of this genetic analysis imply that symptomatic patients with KCNH2 mutations should be cared for more intensively, i.e., they are candidates for AICDs. Because the functional property of the KCNQ1 channel is almost identical to that of Iks (Barhanin et al. 1996; Sanguinetti et al. 1996) , with a dominant K ϩ current in conditions of high sympathetic activity, mutant KCNQ1 alleles may lead to inadequacy of action potential, which would shorten under adrenergic stress. By reducing this stress, -adrenergic blockade therapy may protect carriers of KCNQ1 mutations against syncope.
The evidence reported here provides a good example of the power of genetic diagnosis to direct the selection of appropriate therapy for patients with diseases of heterogeneous genetic etiology.
